Raising hopes for cell-based therapies, UC San Francisco researchers have created the first functioning human thymus tissue from embryonic stem cells, in the laboratory. The researchers showed that, in mice, the tissue can be used to foster the development of white blood cells the body needs to mount healthy immune responses and to prevent harmful autoimmune reactions.
[More]
Novartis announced today that the US Food and Drug Administration has approved Ilaris (canakinumab) for the treatment of active systemic juvenile idiopathic arthritis in patients aged 2 years and older.
[More]
Veloxis Pharmaceuticals A/S today announced that it has submitted a Marketing Authorization Application to the European Medicines Agency seeking approval to market LCP-Tacro for the prevention of organ rejection in kidney transplant patients in the European Union.
[More]
Nanogels are synthetic particles that can be used for drug delivery. They are approximately 100 nm to 200 nm in diameter, and are made from safe, biocompatible materials: a gel-like interior and a lipid exterior.
[More]
Pioneering research led by Johns Hopkins scientists on the use of partially matched bone marrow transplants to wipe out sickle cell disease has been selected as one of the Top 10 Clinical Research Achievements of 2012 by the Clinical Research Forum.
[More]
Bioengineered rat kidneys developed by Massachusetts General Hospital investigators successfully produced urine both in a laboratory apparatus and after being transplanted into living animals.
[More]
Bayer HealthCare (Bayer) and the German Cancer Research Center (DKFZ) will extend their successful strategic research alliance in search of novel cancer therapeutics by focusing their activities also on the field of immunotherapy. Immunotherapies are a promising approach to treat cancer with the aim to selectively reactivate the body's own immune system so that it attacks tumor cells.
[More]
Taking omega-3 fish oils could help to protect against skin cancer, according to researchers at The University of Manchester.
[More]
Avaxia Biologics, Inc., a clinical-stage biopharmaceutical company developing gut-targeted therapeutics, announced today that the first patient has been dosed in a Phase 1b clinical study of AVX-470, an oral anti-TNF antibody, for the treatment of ulcerative colitis.
[More]
UCB announced today two new regulatory filings with the US Food and Drug Administration (FDA) and with the European Medicines Agency (EMA) to extend the marketing authorization for Cimzia (certolizumab pegol) for the treatment of adult patients with active psoriatic arthritis (PsA) and for adult patients with active axial spondyloarthritis (axSpA).
[More]
Novartis announced today that the US Food and Drug Administration (FDA) has approved Zortress (everolimus) for the prophylaxis of organ rejection in adult patients receiving a liver transplant.
[More]
Solid organ transplant recipients have a significant risk for developing Burkitt lymphoma (BL), US researchers have found.
[More]
Metastatic renal cell carcinoma is a devastating disease. There are roughly 20-25,000 new cases per year in the United States and it is increasing for some reason.
[More]
Viracor-IBT Laboratories, Inc. announced today that it has signed a definitive agreement to purchase the assets of Cylex, Inc., a global life sciences company focused on the development, manufacturing and commercialization of in vitro diagnostic products intended to illuminate immunity in the area of transplant medicine.
[More]
Seattle Genetics, Inc. and Millennium: The Takeda Oncology Company, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited (TSE:4502), today announced the initiation of a global phase III clinical trial evaluating ADCETRIS (brentuximab vedotin) in combination with chemotherapy for the treatment of newly diagnosed CD30-positive mature T-cell lymphoma (MTCL) patients, including patients with systemic anaplastic large cell lymphoma (sALCL) and other types of peripheral T-cell lymphomas.
[More]
The results of a pioneering UK-wide clinical trial that compared treatments for patients with a common type of kidney disease has found one to be significantly more effective. The results of the study, published online in The Lancet, will be recommended to clinicians worldwide as the most effective approach to treating the condition.
[More]
Using mesenchymal stromal cells derived from adipose (fat) tissues, genetically modified to express a bioluminescent marker, researchers in Italy have tracked cells after transplantation. The cells were followed from their injection into the spleen of mice modeling liver disease, to their characterization as "hepatic precursors," and to their subsequent migration through the spleen before engrafting at regenerating sites in the liver by bioluminescent imaging.
[More]
Two recent experimental treatments - one involving skin-derived induced pluripotent stem (iPS) cell grafts, the other gene therapy - have been shown to produce long-term improvement in visual function in mouse models of retinitis pigmentosa (RP), according to the Columbia University Medical Center (CUMC) scientists who led the studies. At present, there is no cure for RP, the most common form of inherited blindness.
[More]
Better targeted treatments for 20 per cent of renal failure patients are on the horizon following a key discovery about the role of white blood cells in kidney inflammation.
[More]
The Squash Diabetes Campaign was launched today by the Georgetown University Women's Squash Team, where a team member successfully competes in the vigorous game of squash despite the health challenges of Type 1 (Juvenile) diabetes.
[More]